Table 4.

Summary of Adverse Events

	Denosumab/Alendronate Sequence
	Denosumab Year 1 (N = 125)	Alendronate Year 2 (N = 110)
Adverse events, n (%)
All	93 (74.4)	68 (61.8)
Serious	4 (3.2)	4 (3.6)
Adverse events of interest in either treatment group, n (%)
Arthralgia	11 (8.8)	7 (6.4)
Pain in extremity	9 (7.2)	4 (3.6)
Cough	5 (4.0)	5 (4.5)
Back pain	5 (4.0)	3 (2.7)
Osteoarthritis	2 (1.6)	3 (2.7)
Headache	4 (3.2)	3 (2.7)
Adverse events of fracture,a n (%)	1 (0.8)	1 (0.9)

N = number of participants who received at least 1 dose of investigational product during the corresponding treatment period (safety analysis population); n = number of participants reporting at least 1 adverse event during the corresponding period.

Includes only treatment-emergent adverse events that started on or before the end of the corresponding treatment period.

^aReported fractures were classified as osteoporotic and nonvertebral.